Business
business

Tesla sales fall in Europe’s two biggest EV markets while BYD sales soar

Last month Tesla sales more than halved in Europe’s two biggest EV markets, the UK and Germany, compared with a year earlier. Meanwhile, sales of vehicles from Chinese EV maker BYD more than quadrupled in those countries. The data follows July declines in a number of other European countries reported last week.

BYD outsold Tesla on the continent for the first time earlier this year. The reason, according to Executive Vice President Stella Li: BYD offers way more models that appeal to a wider variety of consumers. To make matters worse, Electrek reported last week that Tesla has stopped taking orders for its Model S and Model X in Europe, leaving just the Model 3 and Model Y (combined they spell “SEXY,” for what it’s worth).

BYD outsold Tesla on the continent for the first time earlier this year. The reason, according to Executive Vice President Stella Li: BYD offers way more models that appeal to a wider variety of consumers. To make matters worse, Electrek reported last week that Tesla has stopped taking orders for its Model S and Model X in Europe, leaving just the Model 3 and Model Y (combined they spell “SEXY,” for what it’s worth).

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services' General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

Hims launched the product last week, a seeming copy of a recently released and patented drug, and immediately drew fire from Novo Nordisk and regulators.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services' General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

Hims launched the product last week, a seeming copy of a recently released and patented drug, and immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26
2025 WWD Beauty CEO Summit - Day 2

CFO Mandy Fields sees e.l.f. Beauty in growth mode, as company beats on sales and earnings

The new owner of rhode beat estimates for its fiscal third quarter and boosted its guidance for the full year, even as headwinds in the UK and Germany continued.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.